Latest News - Danaher
Top Corporates Hub
Danaher
Did Danaher’s (DHR) New AI-Powered Autonomous Lab at Abcam Just Redefine Its Innovation Edge?
09.10.2026 00:23
In early October 2026, Danaher announced it had launched its first AI-powered autonomous lab at Abcam, combining artificial intelligence, robotics and connected workflows to accelerate the design, building and testing of custom antibodies and other molecular tools. The lab’s closed-loop system, which feeds every experimental result back into its AI models, is intended to lift both the speed and scale of reagent discovery while maintaining rigorous validation. Now we’ll examine how this...
Is Danaher (DHR) Undervalued As Its New AI Lab Pushes Faster Antibody Development?
08.10.2026 19:13
Danaher (DHR) has put artificial intelligence at the center of its latest move by outlining plans for an autonomous lab at Abcam that targets faster, more scalable antibody and molecular tool development. The latest autonomous lab announcement comes after a period in which Danaher’s 90-day share price return of 11.49% has outpaced its year-to-date share price decline of 5.17%. The 1-year total shareholder return of 7.39% indicates modest, steadily rebuilding momentum. Scan how Danaher’s move...
Danaher (DHR) Launched Its First AI Powered Autonomous Laboratory
08.10.2026 14:13
Danaher (NYSE:DHR) announced the launch of its first AI powered autonomous laboratory aimed at life sciences research acceleration. The new facility integrates artificial intelligence, robotics, and Danaher proprietary technologies to automate complex experimental workflows. Company materials highlight use cases such as faster development of custom antibodies and other research tools for biomedical customers. Danaher’s AI powered autonomous lab launch is important context to weigh alongside...
Danaher stock rises 2% on AI-powered autonomous lab plans
07.10.2026 13:32
Investing.com -- Danaher Corporation (NYSE:DHR) shares gained 2% in premarket trading Wednesday after the company announced plans to launch its first AI-powered autonomous lab for antibody research.
Danaher Accelerates Life Sciences Research with New AI-powered Autonomous Lab
07.10.2026 11:00
Danaher Corporation (NYSE: DHR) today announced plans to launch its first AI-powered autonomous lab, designed to help researchers develop custom antibodies and other molecular tools faster and more efficiently. Expected to operate at scale in early 2027, the lab will combine artificial intelligence, robotics and technologies from several Danaher operating companies in one connected workflow. It is the first step in a broader Danaher initiative to create smart instruments, integrated workflows an
1 Healthcare Stock with Competitive Advantages and 2 We Find Risky
07.10.2026 08:56
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 36.4% gain over the past six months, beating the S&P 500 by 18.9 percentage points.
Danaher's Multiple Now in Line With Peers, RBC Says
05.10.2026 15:05
Danaher's (DHR) premium multiple has been adjusted to a multiple in line with its peers, after sever
ELV or DHR: Which Is the Better Value Stock Right Now?
05.10.2026 14:40
ELV vs. DHR: Which Stock Is the Better Value Option?
RBC Capital Maintains Outperform on Danaher, Raises Price Target to $250
05.10.2026 09:28
RBC Capital analyst Dan Leonard maintains Danaher (NYSE:DHR) with a Outperform and raises the price target from $215 to $250.
What You Need to Know Ahead of Danaher’s Earnings Release
01.10.2026 11:03
Danaher is heading into its third-quarter earnings report in the coming weeks, and Wall Street expects modest, low-single-digit earnings growth.
Julie Sawyer Montgomery Assumes Role as Danaher President and Chief Executive Officer
01.10.2026 11:00
Danaher Corporation (NYSE: DHR) ("Danaher" or "the Company") announced that, effective today, Julie Sawyer Montgomery has assumed the roles of President and Chief Executive Officer and has joined Danaher's Board of Directors, as previously announced on August 3, 2026. Since joining the Company in 2017, Ms. Sawyer Montgomery has held roles of increasing responsibility spanning commercial operations, R&D, and business leadership. In those roles, she has built a track record of advancing innovation
Guggenheim Maintains Buy on Danaher, Raises Price Target to $250
01.10.2026 09:59
Guggenheim analyst Subbu Nambi maintains Danaher (NYSE:DHR) with a Buy and raises the price target from $200 to $250.
Leica Biosystems Completes Acquisition of StatLab to Bolster Delivery of More Precise, Timely Diagnostics for Cancer Patients
28.09.2026 13:00
Leica Biosystems, a Danaher company (the "Company") and a global leader in digital and anatomic pathology solutions advancing precision cancer diagnostics, announced today that the Company has completed its acquisition of privately held StatLab Medical Products ("StatLab"), a leading provider of pre-analytical consumables and equipment, from Linden Capital Partners and Audax Private Equity. For patients and their care teams, precision cancer diagnostics can provide critical information about the
Danaher Isn't Anything Special, Even After Absorbing Masimo
24.09.2026 02:49
Danaher (DHR) stays a hold: modest core growth and higher leverage after the Masimo acquisition limit upside despite synergies.
MaxCyte Appoints Sidharth Kapileshwar as Chief Corporate Development Officer
23.09.2026 12:05
ROCKVILLE, Md., Sept. 23, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it has appointed Sidharth Kapileshwar as Chief Corporate Development Officer. "Sidharth has a proven track record of building and scaling corporate development functions inside some of the largest healthcare companies in the
Capitalize on the Label-Free Detection Market Shift: Track How Danaher, Sartorius, Agilent, Bruker and Revvity Are Disrupting R&D ROI and Reshaping Global Revenue Through 2030
22.09.2026 08:26
AI-enabled, microfluidic label-free detection is expanding in drug discovery, early diagnostics, food safety and environmental testing, driven by efficient, non-invasive, sustainable workflows.Dublin, Sept. 22, 2026 (GLOBE NEWSWIRE) -- "Label-Free Detection - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Label-Free Detection was valued at US$553 Million in 2024 and is projected to reach US$847 Million by 2030, growing at a CAGR of 7.4
Capitalize on the Label-Free Detection Market Shift: Track How Danaher, Sartorius, Agilent, Bruker and Revvity Are Disrupting R&D ROI and Reshaping Global Revenue Through 2030
22.09.2026 08:26
AI-enabled, microfluidic label-free detection is expanding in drug discovery, early diagnostics, food safety and environmental testing, driven by efficient, non-invasive, sustainable workflows.Dublin, Sept. 22, 2026 (GLOBE NEWSWIRE) -- "Label-Free Detection - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Label-Free Detection was valued at US$553 Million in 2024 and is projected to reach US$847 Million by 2030, growing at a CAGR of 7.4
Capitalize on the Label-Free Detection Market Shift: Track How Danaher, Sartorius, Agilent, Bruker and Revvity Are Disrupting R&D ROI and Reshaping Global Revenue Through 2030
22.09.2026 08:26
AI-enabled, microfluidic label-free detection is expanding in drug discovery, early diagnostics, food safety and environmental testing, driven by efficient, non-invasive, sustainable workflows.Dublin, Sept. 22, 2026 (GLOBE NEWSWIRE) -- "Label-Free Detection - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Label-Free Detection was valued at US$553 Million in 2024 and is projected to reach US$847 Million by 2030, growing at a CAGR of 7.4
2 Unpopular Stocks That Should Get More Attention and 1 We Question
18.09.2026 10:32
Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.
Danaher (DHR) Could Be 8% Below Fair Value Following Its Dividend Reaffirmation
16.09.2026 11:12
Danaher (DHR) has reaffirmed its shareholder payout, with the Board approving a regular quarterly cash dividend of $0.40 per share, payable on October 30, 2026, to holders of record on September 30. The reaffirmed dividend lands at a time when Danaher’s short-term momentum has picked up. The 90-day share price return is 17.78% and the 1-year total shareholder return is 10.73%, even though the 5-year total shareholder return is down 25.46%. Compare Danaher’s mix of dividend income and recent...